Position of the retinological society, the German ophthalmological society and the professional association of ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration: Status as of june 2007;Stellungnahme der retinologischen gesellschaft, der Deutschen ophthalmologischen gesellschaft und des berufsverbands der augenärzte Deutschlands zu aktuellen therapeutischen möglichkeiten bei der neovaskulären altersabhängigen makuladegeneration: Stand Juni 2007

Klinische Monatsblatter fur Augenheilkunde

Volumn 224, Issue 7, 2007, Pages 559-566

  Bartz Schmidt, U ^a   Bertram, B ^a   Bornfeld, N ^a   Grisanti, S ^a   Holz, F ^a   Lemmen, K ^a   Pauleikhoff, D ^a   Roider, J ^a   Walter, P ^a  

^a NONE

Author keywords

Age related macular degeneration; Preferred practice pattern

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GERMANY; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); PHOTODYNAMIC THERAPY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TREATMENT INDICATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; MACULAR DEGENERATION; OPHTHALMOLOGY; PHOTOCHEMOTHERAPY; PORPHYRINS; PREGNADIENEDIOLS; SOCIETIES, MEDICAL; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547789834     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963356     Document Type: Review

References (61)

1. Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskularen altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd 2006; 223: 271-278
2. Bekanntmachungen: Vereinbarung von Qualitätssicherungsmaß nahmen nach § 135 Abs. 2 SGB V zur photodynamischen Therapie am Augenhintergrund (Qualitätssicherungsvereinbarung PDT). Dtsch Ärztebl 2006; 103: A 2575-2577
3. Bekanntmachungen: Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung in Anlage I "Anerkannte Untersuchungs- oder Behandlungsmethoden" vom 19. September 2006. Dtsch Ärztebl 2006; 104: A-74
4. Pauleikhoff D, Bornfeld N, Gabel VP et al. Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte - Stellungnahme zur aktuellen Therapie der neovaskulären AMD. Klin Monatsbl Augenheilkd 2005; 222: 381-388
5. http://www.novartisophthalmics.visudyne.de/Visudyne/index_pro.xml? view=db&menuid=1663&linkid=3859
6. Gillies MC, Simpson JM, Luo W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121: 667-673
7. Jonas JB, Spandau UH, Kamppeter BA et al. Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration. J Ocul Pharmacol Ther 2006; 22: 194-199
8. Jonas JB, Spandau UH, Kamppeter BA et al. Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration. Ophthalmic Res 2006; 38: 324-328
9. Jonas JB, Spandau UH, Kamppeter BA et al. Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye 2007; 21: 387-394
10. Russell SR, Hudson HL, Jerdan JA. Anecortave acetate for the treatment of exudative age-related macular degeneration - a review of clinical outcomes. Surv Ophthalmol 2007; 52 (Suppl 1): S79-90
11. Slakter JS, Bochow TW, D'Amico DJ et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113: 3-13
12. Gonzales CR. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25: 815-827
13. Gragoudas ES, Adamis AP, Cunningham ET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816
14. Chakravarthy U, Adamis AP, Cunningham ET Jr et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508-1521
15. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006; 37: 446-454
16. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444
17. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
18. Novartis Pharma GmbH. Fachinformation Lucentis®. Rote Liste GmbH, 2007
19. http://www.novartis.de/Lucentis
20. Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007; 356: 747-748
21. Heiduschka P, Fietz H, Hofmeister S et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823
22. Spirzer MS, Yoeruek E, Sierra A et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007; im Druck
23. Moschos MM, Brouzas D, Apostolopoulos M et al. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study: Multifocal-ERG after use of bevacizumab in ARMD. DOC Ophthalmol 2007; 114: 37-44
24. Bakri SJ, Snyder MR, Pulido JS et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006; 26: 519-522
25. Peters S, Julien S, Heiduschka P et al. Anti-permeability and anti-proliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91: 827-831
26. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143: 510-512
27. Aisenbrey S, Ziemssen F, Volker M et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948
28. Yoganathan P, Deramo VA, Lai JC et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26: 994-998
29. Jonas JB, Libondi T, Ihloff AK et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007; im Druck
30. Mennel S, Callizo J, Schmidt JC et al. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin®) injections. Acta Ophthalmol Scand 2007; im Druck
31. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-1705
32. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349
33. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007; 85: 119-120
34. Aggio FB, Farah ME, de Melo GB et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 2007; 21: 408-409
35. Gelisken F, Ziemssen F, Voelker M et al. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol Scand 2006; 84: 833-834
36. Meyer CH, Mennel S, Schmidt JC et al. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006; 90: 1207-1208
37. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525
38. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005; 25: 685-690
39. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 14-22
40. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006; 141: 149-156
41. Jonas JB, Kreissig I, Spandau UH et al. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006; 141: 579-580
42. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638-645
43. Chan WM, Lai TV, Wong AL et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006; 90: 337-341
44. Liggett PE, Colina J, Chaudhry NA et al. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006; 142: 1072-1074
45. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140
46. Shen J, Samul R, Silva RL et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225-234
47. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293: 1509-1513
48. http://www.cebm.net/downloads/Oxford_CEBM_Levels_5.rtf
49. Francke R, Hart D. Off label use - Arzneimittelrechtliche, haftungsrechtliche, berufsrechtliche und sozialrechtliche Fragen. Die Sozialgerichtsbarkeit 2003; 50: 653-664
50. nd, Sternberg P Jr. Does "off-label" mean off limits for patient care? Am J Ophthalmol 2007; 143: 853-855
51. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-1114
52. Voelker M, Gelisken F, Ziemssen F et al. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1241-1246
53. Dhalla MS, Shah GK, Blinder KJ et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26: 988-993
54. Axer-Siegel R, Ehrlich R, Rosenblatt I et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 2004; 122: 453-459
55. Axer-Siegel R, Ehrlich R, Avisar I et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging 2006; 37: 455-461
56. Sutter FK, Kurz-Levin MM, Fleischhauer J et al. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monatsbl Augenheilkd 2006; 223: 376-378
57. Nicolo M, Ghiglione D, Lai S et al. Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1336-1338
58. Bolz M, Michels S, Geitzenauer W et al. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 2006; 91: 785-789
59. Gamulescu MA, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1037-1040
60. Aiello LP, Brucker AJ, Chang S et al. Evolving guidelines for intravitreous injections. Retina 2004; 24: S3-S19
61. Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007; 27: 10-12